Dolutegravir (GSK1349572)

For research use only.

Catalog No.S2667 Synonyms: S/GSK1349572

19 publications

Dolutegravir (GSK1349572) Chemical Structure

CAS No. 1051375-16-6

Dolutegravir (GSK1349572, S/GSK1349572) is a two-metal-binding HIV integrase inhibitor with IC50 of 2.7 nM in a cell-free assay, modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 450 In stock
USD 270 In stock
USD 370 In stock
USD 970 In stock
USD 2670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Dolutegravir (GSK1349572) has been cited by 19 publications

Purity & Quality Control

Choose Selective Integrase Inhibitors

Biological Activity

Description Dolutegravir (GSK1349572, S/GSK1349572) is a two-metal-binding HIV integrase inhibitor with IC50 of 2.7 nM in a cell-free assay, modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.
Features A next-generation and two-metal-binding HIV integrase strand transfer inhibitor.
Targets
HIV integrase [2]
(Cell-free assay)
2.7 nM
In vitro

S/GSK1349572 shows the potent inhibitory effect on nine clinical isolates from integrase inhibitor-naive HIV-2-infected patients with EC50 ranging from 0.2 nM -1.4 nM. [1] In vitro, S/GSK1349572 inhibits recombinant HIV-1 integrase-catalyzed strand transfer with IC50 of 2.7 nM. Furthermore, S/GSK1349572 potently inhibits HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector with EC50 of 0,51 nM, 0.71 nM and 2.2 nM, respectively. [2] In vitro, S/GSK1349572 exhibits potent activity against five different nonnucleoside reverse transcription inhibitor--resistant or nucleoside reverse transcription inhibitor--resistant viruses with EC50 ranging from 1.3 nM -2.1 nM. Similarly to that against wild-type virus, S/GSK1349572 shows equivalent activity against two protease inhibitor-resistant viruses with EC50 of 0.36 nM and 0.37 nM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDCK2 cells M{\WWmZ2dmO2aX;uJIF{e2G7 NFLzV4VKdmirYnn0bY9vKG:oIHj1cYFvKE:FVEKg[ZhxemW|c3XkJIlvKE2GQ1uyJINmdGy|IIXzbY5oKFtzNFPdcYV1\m:{bXnuJIF{KHO3YoP0doF1\SCkeTDsbZF2cWRic3PpcpRqdGyjdHnvckBkd3WwdHnu[{BidmGueYPpdy=> M37SPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUOyN|M1Lz5{M{GzNlM{PDxxYU6=
HOS M{TuPWFvfGm4aYLhcEBie3OjeR?= NFXOeZg{KGi{cx?= MXTBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYuOSCqYYLic5Jqdmdid3ns[EB1gXCnIHnueIVoemG|ZTDpcoZm[3SnZDDpckBpfW2jbjDIU3Mh[2WubIOgdJJmfHKnYYTl[EB4cXSqIHPvcZBwfW6mIH\vdkA{KGi{czDifUB{cW6pbHWtdo92dmRiSFnWMVEhcW6oZXP0bZZqfHliYYPzZZktKEWFNUCgQUAxNjByMU[g{txONg>? M{LzRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCxOlY4Lz5{NEmwNVY3PzxxYU6=
HEK293T MmjqRY51cX[rcnHsJIF{e2G7 MXOyJIRigXN? MlnFRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgdJNmfWSxIFj1cYFvKGmvbYXuc4Rm\mmlaXXuZ5khfmm{dYOgbY5n\WO2ZXSgbY4hUEWNMkmzWEBk\WyuczDh[pRmeiB{IHThfZMtKEmFNUCgQUAxNjByMUeg{txONg>? M4TFOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OES1NVgxLz5{M{i0OVE5ODxxYU6=
MT4 M3ro[WFvfGm4aYLhcEBie3OjeR?= MoPhOEB1dyB3IHThfZM> MnvQRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTJVu[W5iaX3teY5w\GWoaXPp[Y5kgSC4aYL1d{AyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIF3UOEBk\WyuczDh[pRmeiB2IITvJFUh\GG7czDifUBjcW:udX3pcoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkCwNkDPxE1w NYfYOIhvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFUyQDBpPkKzPFQ2OThyPD;hQi=>
HOS MXLBcpRqfmm{YXygZZN{[Xl? NX;yWG01OyCqcoO= MlP1RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgdoFtfGWpcnH2bZIuemW|aYP0ZY51KEiLVj2xJIhiemKxcnnu[{BqdnSnZ4Lhd4UhVjF3NVigcZV1[W62IHnu[oVkfGWmIHnuJIh2dWGwIFjPV{Bk\WyuczDwdoV1emWjdHXkJJdqfGhiY3;tdI92dmRiZn;yJFMhcHK|IHL5JJNqdmeuZT3yc5Vv\CCKSW[tNUBqdm[nY4Tpeol1gSCjc4PhfUwhTUN3MDC9JFAvODB|NjFOwG0v MkLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEG2OlcoRjJ2OUCxOlY4RC:jPh?=
HOS MV\BcpRqfmm{YXygZZN{[Xl? MonkN{BpenN? NUf0eZR{SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhemGudHXndoF3cXJvcnXzbZN1[W62IFjJWk0yKGijcnLvdolv\yCrboTl[5Jie2ViWUG0N3IhdXW2YX70JIlv\mWldHXkJIlvKGi3bXHuJGhQWyClZXzsd{BxemW2cnXheIVlKHerdHigZ49ueG:3bnSg[o9zKDNiaILzJIJ6KHOrbnfs[U1zd3WwZDDITXYuOSCrbn\lZ5Rqfmm2eTDhd5NigSxiRVO1NEA:KDBwMEC0N{DPxE1w MmTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEG2OlcoRjJ2OUCxOlY4RC:jPh?=
HOS MVrBcpRqfmm{YXygZZN{[Xl? MYSzJIhzew>? Mn:2RY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgdoFtfGWpcnH2bZIuemW|aYP0ZY51KEiLVj2xJIhiemKxcnnu[{BqdnSnZ4Lhd4UhTzF2MGOvVVE1QEhiZH;1ZoxmKG23dHHueEBqdm[nY4Tl[EBqdiCqdX3hckBJV1NiY3XscJMheHKndILlZZRm\CC5aYToJINwdXCxdX7kJIZweiB|IHjyd{BjgSC|aX7ncIUuem:3bnSgTGlXNTFiaX7m[YN1cX[rdImgZZN{[XluIFXDOVAhRSByLkCwOVgh|ryPLh?= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMU[2O{c,OjR7MEG2Olc9N2F-
HOS Mlj2RY51cX[rcnHsJIF{e2G7 NWrOSnZ1OyCqcoO= M4HN[mFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGlPW1SLLYLld4l{fGGwdDDITXYuOSCqYYLic5JqdmdiaX70[Ydz[XOnIGKyOlNMKG23dHHueEBqdm[nY4Tl[EBqdiCqdX3hckBJV1NiY3XscJMheHKndILlZZRm\CC5aYToJINwdXCxdX7kJIZweiB|IHjyd{BjgSC|aX7ncIUuem:3bnSgTGlXNTFiaX7m[YN1cX[rdImgZZN{[XluIFXDOVAhRSByLkCxNUDPxE1w MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMU[2O{c,OjR7MEG2Olc9N2F-
HOS M1rVeWFvfGm4aYLhcEBie3OjeR?= MoO5N{BpenN? Ml\URY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTW5UXElvcnXzbZN1[W62IFjJWk0yKGijcnLvdolv\yCrboTl[5Jie2ViR{GxPHIhdXW2YX70JIlv\mWldHXkJIlvKGi3bXHuJGhQWyClZXzsd{BxemW2cnXheIVlKHerdHigZ49ueG:3bnSg[o9zKDNiaILzJIJ6KHOrbnfs[U1zd3WwZDDITXYuOSCrbn\lZ5Rqfmm2eTDhd5NigSxiRVO1NEA:KDBwMEGzJO69VS5? MoH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEG2OlcoRjJ2OUCxOlY4RC:jPh?=
P4R5 MAGI MUTBcpRqfmm{YXygZZN{[Xl? Mn;BNlQhcHK| NFLJTnRCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIHnu[oVkfGWmIHnuJGNFPC:FWFPSOE9ES1J3IHX4dJJme3OrbnegbJVu[W5iUETSOUBOSUeLIHPlcIx{KHC{ZXnuZ5Vj[XSnZDD3bZRpKGOnbHzzJIZweiB{NDDodpMh\m:ubH;3[YQh[nlidnnyZYwhcW6oZXP0bY9vKG2nYYP1doVlKGGodHXyJFQ5KGi{czDifUBj\XSjLXfhcIFkfG:|aXThd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NEA:KDBwMEKg{txONg>? MmizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{G5O|YoRjNyMEOxPVc3RC:jPh?=
P4R5 NYnwb4JjSW62aY\pdoFtKGG|c3H5 MmfqNlQhcHK| M{WzSmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiaX7m[YN1\WRiaX6gR2Q1N0O[Q2K0M2NEWjViZYjwdoV{e2mwZzDoeY1idiCSNGK1JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidnnyZYwhemWybHnjZZRqd25icILlbY5kfWKjdHXkJJdqfGhiY3XscJMh\m:{IEK0JIhzeyCob3zsc5dm\CCkeTD2bZJidCCrbn\lZ5Rqd25ibXXhd5Vz\WRiYX\0[ZIhPDhiaILzJIJ6KGKndHGt[4Ft[WO2b4Pp[IF{\SC{ZYDvdpRmeiCpZX7lJIF{eyxiRVO1NEA:KDBwMEKg{txONg>? Mmn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3MkWyO|koRjJ6NUK1Nlc6RC:jPh?=
HEK293T M37qVmFvfGm4aYLhcEBie3OjeR?= MkfqNkBl[Xm| M1jPZWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JJB{\XWmbzDIeY1idiCrbX31co9l\W[rY3nlcoN6KH[rcoXzJIlv\mWldHXkJIlvKEiHS{K5N3Qh[2WubIOgZYZ1\XJiMjDkZZl{KGmwIIDy[ZNmdmOnIH;mJIh2dWGwIIPldpVuKGGuYoXtbY4tKEmFNUCgQUAxNjB{MjFOwG0v NGLJPW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OVE5OCd-MkO4OFUyQDB:L3G+
MDCK2 MnrvSpVv[3Srb36gZZN{[Xl? NEfCWINKdmirYnn0bY9vKG:oIHj1cYFvKE:FVEKg[ZhxemW|c3XkJIlvKE2GQ1uyJINmdGy|IIXzbY5oKFtzNFPdcYV1\m:{bXnuJIF{KHO3YoP0doF1\SCkeTDsbZF2cWRic3PpcpRqdGyjdHnvckBkd3WwdHnu[{BidmGueYPpd{whUUN3MDC9JFEvQSEQvF2u MkPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzM{KzN|QoRjJ|MUOyN|M1RC:jPh?=
Vero E6 MUDBcpRqfmm{YXygZZN{[Xl? MVWyJIRigXN? MXnBcpRqfmm{YXyg[YZncWOjY4mgZYdicW6|dDDTRXJUNUOxVj2yJEh{fHKjaX6gRoF3WGG2MTmgbY4hXmW{bzDFOkBk\WyuczDhd5Nme3OnZDDifUBqdmirYnn0bY9vKG:oII\pdoFtKFKQQTDy[ZBtcWOjdHnvckBu\WG|dYLl[EBjgSCUVD3QR3Ih[W[2ZYKgNkBl[Xm|LDDFR|UxKD1iMkKuNFQh|ryPLh?= NH7rbHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjJ7MkGxM{c,S2iHTVLMQE9iRg>?
Vero E6 Mmr4RY51cX[rcnHsJIF{e2G7 MVuyJIRigXN? MnHWRY51cX[rcnHsJIVn\mmlYXP5JIFo[Wmwc4SgV2FTWy2Fb2[tNkApe3S{YXnuJGJiflCjdEGpJIlvKF[ncn:gSVYh[2WubIOgZZN{\XO|ZXSgZpkhcW6qaXLpeIlwdiCxZjD2bZJidCCUTlGgdoVxdGmlYYTpc44hdWWjc4Xy[YQh[nliUmStVGNTKGGodHXyJFIh\GG7czygSWM6OCB;IESyMlgyKM7:TT6= M4nUU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOjl{MUGvK|5EcEWPQly8M4E,

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Dose-response infectivity curves
NL4.3IN(WT) / NL4.3IN(S230R) virus; 

PubMed: 29617824     


Dose-response infectivity curves in the presence of dolutegravir (DTG) for wild-type (WT) and S230R viruses. Data reflect viral resistance to DTG in TZM-bl cells. TZM-bl cells were infected with NL4.3IN(WT) or NL4.3IN(S230R) virus over 48 hours, and luciferase levels were measured. Infectivity of NL4.3IN(WT) virus is shown for comparison. Dose-response curves were produced from the compilation of 3 independent experiments, each performed in triplicate. Error bars indicate means (±standard errors of the mean). RLU, relative luminescence units.

29617824

Protocol

Kinase Assay:

[2]

- Collapse

In vitro strand transfer assay:

The inhibitory potencies of S/GSK1349572 and other INIs are measured in a strand transfer assay using recombinant HIV integrase. A complex of integrase and biotinylated preprocessed donor DNA-streptavidin-coated Acintillation proximity assay (SPA) beads is formed by incubating 2 μM purified recombinant integrase with 0.66 μM biotinylated donor DNA-4 mg/mL streptavidin-coated SPA beads in 25 mM sodium morpholinepropanesulfonic acid (MOPS) (pH 7.2), 23 mM NaCl, and 10 mM MgCl2 for 5 minutes at 37 °C. These beads are spun down and preincubated with diluted INIs for 60 minutes at 37 °C. Then a 3H-labeled target DNA substrate is added to give a final concentration of 7 nM substrate, and the strand transfer reaction mixture is incubated at 37 °C for 25 to 45 minutes, which allows for a linear increase in the strand transfer of donor DNA to radiolabeled target DNA. The signal is read using a Wallac MicroBeta scintillation plate reader.
Cell Research:

[2]

- Collapse
  • Cell lines: MT-4
  • Concentrations: 0 to 10 μM
  • Incubation Time: 4 days or 5 days
  • Method:

    MT-4 cells growing exponentially at a density of 500000 or 600000 /mL are infected with HIV-1 strain IIIB at a viral multiplicity of infection of 0.001 or a 50% tissue culture infective dose of 4 to 10. The cells are then aliquoted to 96-well plates in the presence of varying concentrations of S/GSK1349572. After incubation for 4 or 5 days, antiviral activity is determined by a cell viability assay that either measured bioluminescence with a CellTiter-Glo luminescent reagent or measured absorbance at 560 and 690 nm using the yellow tetrazolium MTT reagent [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide].


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 83 mg/mL warmed (197.91 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 419.38
Formula

C20H19F2N3O5

CAS No. 1051375-16-6
Storage powder
in solvent
Synonyms S/GSK1349572
Smiles CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04166474 Not yet recruiting Drug: Dolutegravir Hiv|Tuberculosis Helen Reynolds|Infectious Disease Institute Kampala Uganda|Desmond Tutu HIV Centre|University of Liverpool April 2021 Phase 4
NCT04771754 Not yet recruiting Drug: Dolutegravir HIV-1-infection Chelsea and Westminster NHS Foundation Trust February 19 2021 Phase 1
NCT04133012 Recruiting Other: Samplings HIV-1 Infection ANRS Emerging Infectious Diseases|ViiV Healthcare February 10 2020 Not Applicable
NCT03851588 Recruiting Other: Placebo|Drug: Dolutegravir 50 mg HIV Infections|Tuberculosis University of Cape Town|Wellcome Trust|Medecins Sans Frontieres Netherlands December 19 2019 Phase 2
NCT04034862 Not yet recruiting Drug: Treatment simplification (dolutegravir lamivudine) HIV Infections University of Liege October 1 2019 Phase 3
NCT03991013 Recruiting Drug: Dolutegravir 50 mg|Drug: Placebo HIV Infections University of Cape Town|Wellcome Trust|Médecins Sans Frontières Belgium August 8 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Integrase Signaling Pathway Map

Related Integrase Products

Tags: buy Dolutegravir (GSK1349572) | Dolutegravir (GSK1349572) supplier | purchase Dolutegravir (GSK1349572) | Dolutegravir (GSK1349572) cost | Dolutegravir (GSK1349572) manufacturer | order Dolutegravir (GSK1349572) | Dolutegravir (GSK1349572) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID